Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2020; 26(35): 5362-5374
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5362
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5362
Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease
Sofia Kärnsund, Bobby Lo, Flemming Bendtsen, Johan Burisch, Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre 2650, Denmark
Jakob Holm, Department of Endocrinology, Copenhagen University Hospital Herlev, Herlev 4600, Denmark
Author contributions: All authors have made significant contributions to the research in this study; all authors approved the submitted version of the manuscript and the authorship list; Kärnsund S and Lo B contributed to acquisition, interpretation and analysis of data; Kärnsund S contributed to writing of manuscript; Lo B contributed to critical revision for important intellectual content; Bendtsen F and Burisch J contributed to conception and design of study, critical revision for important intellectual content; Burisch J contributed to finally approval of submitted manuscript.
Conflict-of-interest statement: Burisch J received consulting fees from Celgene, Janssen-Cilag, AbbVie, Tillots Pharma and Ferring; lecture fees from Abbvie, Pfizer, MSD, Pharmacosmos and Takeda Pharma; unrestricted grant support from Takeda Pharma, MSD, AbbVie and Tillots Pharma. Holm J has participated as a sub investigator in studies by Amgen and MSD and received payment for lectures sponsored by Amgen and LEO Pharma. Kärnsund S, Lo B and Bendtsen F have nothing to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Sofia Kärnsund, BSc, Doctor, Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Kettegård Alle 30, Hvidovre 2650, Denmark. sofiakarnsund@hotmail.com
Received: March 28, 2020
Peer-review started: March 28, 2020
First decision: April 25, 2020
Revised: May 4, 2020
Accepted: August 22, 2020
Article in press: August 22, 2020
Published online: September 21, 2020
Processing time: 172 Days and 8.2 Hours
Peer-review started: March 28, 2020
First decision: April 25, 2020
Revised: May 4, 2020
Accepted: August 22, 2020
Article in press: August 22, 2020
Published online: September 21, 2020
Processing time: 172 Days and 8.2 Hours
Core Tip
Core Tip: Being diagnosed with inflammatory bowel disease (IBD) is considered a risk factor for development of osteoporosis, which leads to an increased risk of pathological fractures. This makes osteoporosis associated with great economic and psychological burden. Research made on the relationship between IBD and osteoporosis differs in study design and study populations, and results are inconsistent. The aims with this research are to assess the prevalence of osteoporosis among IBD patients compared to healthy individuals, assess the disease course of osteoporosis or low bone mineral density (BMD) in IBD patients and assess risk factors associated with osteoporosis and low BMD in IBD patients.